InterventionsIn silico

Sodium–Glucose Cotransporter 2 Inhibitors are Cost-Effective and Dominate Glucagon-Like Peptide-1 Receptor Agonists for Patients with Type 2 Diabetes and High Cardiorenal Risk in Canada

AHA Scientific Sessions 2025 Abstract

The paper

Abhinav Sharma, Ethan McNally, Pedro Marques,

Elite Possik, Ankur Pandya, Michael A. Tsoukas, Thomas A. Mavrakanas, Kaberi Dasgupta, Nisha Gupta,

W. Alton Russell

McGill University Health Centre · McGill University

AHA Scientific Sessions 2025 Abstract · 3 Nov 2025

Presented at AHA Scientific Sessions 2025 · Abstract 4345655

doi.org/10.1161/circ.152.suppl_3.4345655

GLP-1 drugs added to SGLT2 inhibitors linked to lower kidney risk
Diabetes, Obesity & Metabolism · 4 Oct 2026
SGLT2 inhibitors match GLP-1 drugs for overall kidney outcomes
Clinical Journal of the American Society of Nephrology · 4 Oct 2026
SGLT2 inhibitors link to lower dementia risk than GLP-1 drugs
Diabetes & Vascular Disease Research · 4 Oct 2026
Drug class linked to fewer deaths or complications in kidney disease
The American Journal of Cardiology · 8 Oct 2026